1
|
Ladetto M, Tavarozzi R, Zanni M, Evangelista A, Ferrero S, Tucci A, Botto B, Bolis S, Volpetti S, Zilioli VR, Puccini B, Arcari A, Pavone V, Gaidano G, Corradini P, Tani M, Cavallo F, Milone G, Ghiggi C, Pinto A, Pastore D, Ferreri AJM, Latte G, Patti C, Re F, Benedetti F, Luminari S, Pennese E, Bossi E, Boccomini C, Anastasia A, Bottelli C, Ciccone G, Vitolo U. Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial. Ann Oncol 2024; 35:118-129. [PMID: 37922989 DOI: 10.1016/j.annonc.2023.10.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2023] [Revised: 09/11/2023] [Accepted: 10/03/2023] [Indexed: 11/07/2023] Open
Abstract
BACKGROUND Optimal consolidation for young patilents with relapsed/refractory (R/R) follicular lymphoma (FL) remains uncertain in the rituximab era, with an unclear benefit of autologous stem cell transplantation (ASCT). The multicenter, randomized, phase III FLAZ12 (NCT01827605) trial compared anti-CD20 radioimmunotherapy (RIT) with ASCT as consolidation after chemoimmunotherapy, both followed by rituximab maintenance. PATIENTS AND METHODS Patients (age 18-65 years) with R/R FL and without significant comorbidities were enrolled and treated with three courses of conventional, investigator-chosen chemoimmunotherapies. Those experiencing at least a partial response were randomized 1 : 1 to ASCT or RIT before CD34+ collection, and all received postconsolidation rituximab maintenance. Progression-free survival (PFS) was the primary endpoint. The target sample size was 210 (105/group). RESULTS Between August 2012 and September 2019, of 164 screened patients, 159 were enrolled [median age 57 (interquartile range 49-62) years, 55% male, 57% stage IV, 20% bulky disease]. The study was closed prematurely because of low accrual. Data were analyzed on 8 June 2023, on an intention-to-treat basis, with a 77-month median follow-up from enrollment. Of the 141 patients (89%), 70 were randomized to ASCT and 71 to RIT. The estimated 3-year PFS in both groups was 62% (hazard ratio 1.11, 95% confidence interval 0.69-1.80, P = 0.6662). The 3-year overall survival also was similar between the two groups. Rates of grade ≥3 hematological toxicity were 94% with ASCT versus 46% with RIT (P < 0.001), and grade ≥3 neutropenia occurred in 94% versus 41%, respectively (P < 0.001). Second cancers occurred in nine patients after ASCT and three after radioimmunotherapy (P = 0.189). CONCLUSIONS Even if prematurely discontinued, our study did not demonstrate the superiority of ASCT versus RIT. ASCT was more toxic and demanding for patients and health services. Both strategies yielded similar, favorable long-term outcomes, suggesting that consolidation programs milder than ASCT require further investigation in R/R FL.
Collapse
Affiliation(s)
- M Ladetto
- Department of Translational Medicine, University of Eastern Piedmont, Novara; SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria.
| | - R Tavarozzi
- Department of Translational Medicine, University of Eastern Piedmont, Novara; SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria
| | - M Zanni
- SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria
| | - A Evangelista
- SSD of Clinical Epidemiology, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - S Ferrero
- Department of Molecular Biotechnologies and Health Sciences, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - A Tucci
- Department of Hematology, Spedali Civili, Brescia
| | - B Botto
- Struttura Complessa Ematologia, AOU Città della salute e della scienza di Torino, Turin
| | - S Bolis
- SC Ematologia ASST-Monza, Monza
| | - S Volpetti
- Division of Hematology, Clinica Ematologica, Centro Trapianti e Terapie Cellulari Carlo Melzi, DISM, Azienda Ospedaliero Universitaria S. M. Misericordia, Udine
| | - V R Zilioli
- Division of Haematology, ASST Grande Ospedale Metropolitano Niguarda, Milano
| | - B Puccini
- Department of Haematology, University of Florence, Firenze
| | - A Arcari
- Hematology Unit, Ospedale Guglielmo da Saliceto, Piacenza
| | - V Pavone
- A. O. C. Panico-U.O.C Ematologia e Trapianto, Tricase, Lecce
| | - G Gaidano
- SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria; Division of Hematology, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara
| | - P Corradini
- Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milano
| | - M Tani
- Hematology Unit, Department of Oncology and Hematology, "Santa Maria delle Croci" Hospital, Ravenna
| | - F Cavallo
- Department of Molecular Biotechnologies and Health Sciences, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - G Milone
- Division of Hematology and Program for Hematopoietic Transplantation, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania
| | - C Ghiggi
- Hematology Division, IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova
| | - A Pinto
- Department of Hematology, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico "Fondazione G Pascale", Naples
| | | | - A J M Ferreri
- Onco-Hematology Department, Fondazione Centro San Raffaele, Milano
| | - G Latte
- Unità di Ematologia e Trapianto di Midollo Osseo, San Francesco Hospital, Nuoro
| | - C Patti
- Divisione di Oncoematologia, Azienda Villa Sofia - Cervello, Palermo
| | - F Re
- Department of Hematology, A.O.U. di Parma, Parma
| | - F Benedetti
- Department of Medicine, Section of Hematology and Bone Marrow Transplant Unit, University of Verona, Verona
| | - S Luminari
- Department of Hematology, IRCCS Reggio Emilia, Reggio Emilia
| | - E Pennese
- Lymphoma Unit, Department of Hematology, Ospedale Spirito Santo, Pescara
| | - E Bossi
- SC Ematologia ASST-Monza, Monza
| | - C Boccomini
- Struttura Complessa Ematologia, AOU Città della salute e della scienza di Torino, Turin
| | - A Anastasia
- Department of Hematology, Spedali Civili, Brescia
| | - C Bottelli
- Department of Hematology, Spedali Civili, Brescia
| | - G Ciccone
- SSD of Clinical Epidemiology, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - U Vitolo
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
| |
Collapse
|
2
|
Pulsoni A, Tosti ME, Ferrero S, Luminari S, Dondi A, Liberati AM, Cenfra N, Renzi D, Zanni M, Boccomini C, Ferreri AJ, Rattotti S, Zilioli VR, Bernuzzi P, Bolis S, Musuraca G, Nassi L, Perrone T, Stelitano C, Anastasia A, Corradini P, Partesotti G, Re F, Cencini E, Mannarella C, Mannina D, Molinari AL, Tani M, Annechini G, Assanto GM, Grapulin L, Guarini A, Cavalli M, De Novi LA, Ciabatti E, Mantoan B, Della Starza I, Arcaini L, Ricardi U, Gattei V, Galimberti S, Ladetto M, Foà R, Del Giudice I. UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD‐DRIVEN IMMUNOTHERAPY IN EARLY‐STAGE FOLLICULAR LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.31_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A. Pulsoni
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - M. E. Tosti
- Istituto Superiore di Sanità National Center for Global Health Roma Italy
| | - S. Ferrero
- Hematology Division University of Torino/AOU "Città della Salute e della Scienza di Torino" Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - S. Luminari
- Hematology Unit Arcispedale S. Maria Nuova, Azienda Unità Sanitaria Locale ‐ IRCCS, University of Modena and Reggio Emilia Reggio Emilia Italy
| | - A. Dondi
- Fondazione Italiana Linfomi Onlus, (FIL) Modena Italy
| | - A. M. Liberati
- A.O. Santa Maria Terni, University of Perugia Perugia Italy
| | - N. Cenfra
- Hematology Unit, S. Maria Goretti Hospital AUSL Latina Latina Italy
| | - D. Renzi
- Hematology and Stem Cells Transplantation Unit IRCCS Istituto Nazionale dei Tumori Regina Elena Roma Italy
| | - M. Zanni
- Division of Hematology, SS. Antonio e Biagio Hospital Alessandria Italy
| | - C. Boccomini
- Hematology Department Città della Salute e della Scienza Torino Italy
| | - A. J. Ferreri
- Lymphoma Unit IRCCS San Raffaele Scientific Institute Department of Onco‐Haematology Milano Italy
| | - S. Rattotti
- Division of Hematology Fondazione IRCCS Policlinico San Matteo Pavia Italy
| | - V. R. Zilioli
- Division of Hematology ASST Grande Ospedale Metropolitano Niguarda Milano Italy
| | - P. Bernuzzi
- Hematology Unit, Guglielmo da Saliceto Hospital Department of Onco‐Hematology Piacenza Italy
| | - S. Bolis
- Hematology Department ASST San Gerardo University Hospital Monza Italy
| | - G. Musuraca
- Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori” Meldola (FC) Italy
| | - L. Nassi
- Division of Hematology University of Eastern Piedmont Department of Translational Medicine Novara Italy
| | - T. Perrone
- Unit of Hematology with Transplantation University of Bari, Dept. of Emergency and Organ Transplantation Bari Italy
| | - C. Stelitano
- Department of Haematology Azienda Ospedaliera Bianchi Melacrino Morelli Reggio Calabria Italy
| | - A. Anastasia
- Hematology, ASST Spedali Civili di Brescia Brescia Italy
| | - P. Corradini
- Division of Hematology Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milano Italy
| | - G. Partesotti
- Onco‐Hematology Department Nuovo ospedale civile of Sassuolo Sassuolo Italy
| | - F. Re
- Hematology Clinic, A.O.U. di Parma Parma Italy
| | - E. Cencini
- Unit of Hematology Azienda Ospedaliera Universitaria Senese & University of Siena Siena Italy
| | - C. Mannarella
- Hematology Unit "Madonna delle Grazie" Hospital Matera Italy
| | - D. Mannina
- Department of Hematology Azienda Ospedaliera Papardo Messina Italy
| | | | - M. Tani
- Hematology Unit Santa Maria delle Croci Hospital Ravenna Italy
| | - G. Annechini
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - G. M. Assanto
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - L. Grapulin
- Department of Radiotherapy Policlinico Umberto I, Sapienza University Roma Italy
| | - A. Guarini
- Hematology, Sapienza University Department of Molecular Medicine Roma Italy
| | - M. Cavalli
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - L. A. De Novi
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - E. Ciabatti
- Section of Hematology, University of Pisa Department of Clinical and Experimental Medicine Pisa Italy
| | - B. Mantoan
- Hematology Division University of Torino Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - I. Della Starza
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - L. Arcaini
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo University of Pavia, Department of Molecular Medicine Pavia Italy
| | - U. Ricardi
- Radiation Oncology, University of Turin Department of Oncology Torino Italy
| | - V. Gattei
- Clinical and Experimental Onco‐Hematology Unit CRO Aviano National Cancer Institute Aviano Italy
| | - S. Galimberti
- Section of Hematology University of Pisa, Department of Clinical and Experimental Medicine Pisa Italy
| | - M. Ladetto
- Hematology, Az Ospedaliera Santi Antonio e Biagio e Cesare Arrigo Università del Piemonte Orientale Alessandria Italy
| | - R. Foà
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - I. Del Giudice
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| |
Collapse
|
3
|
Massaro F, Pavone V, Stefani PM, Botto B, Pulsoni A, Patti C, Cantonetti M, Visentin A, Scalzulli PR, Rossi A, Galimberti S, Cimminiello M, Gini G, Musso M, Sorio M, Arcari A, Zilioli VR, Bari A, Mannina D, Fabbri A, Pietrantuono G, Annibali O, Tafuri A, Prete E, Mulè A, Barbolini E, Marcheselli L, Luminari S, Merli F. BRENTUXIMAB VEDOTIN CONSOLIDATION AFTER AUTOLOGOUS STEM CELLS TRANSPLANTATION FOR HODGKIN LYMPHOMA: A REAL‐LIFE EXPERIENCE BY FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2021. [DOI: 10.1002/hon.65_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- F. Massaro
- PhD Program in Clinical and Experimental Medicine, University of Modena and Reggio Emilia Modena Italy
| | - V. Pavone
- Department of Hematology and Bone Marrow Transplant Hospital Card. G. Panico Tricase Italy
| | - P. M. Stefani
- Hematology Unit, General Hospital Ca' Foncello Treviso Italy
| | - B. Botto
- Division of Hematology, Città della Salute e della Scienza Hospital and University Turin Italy
| | - A. Pulsoni
- Hematology Unit, Department of Translational and Precision Medicine, Sapienza University Rome Italy
| | - C. Patti
- Division of Hematology, Azienda Villa Sofia‐Cervello Palermo Italy
| | - M. Cantonetti
- Unit of Lymphoproliferative Disorders, Policlinico Tor Vergata Rome Italy
| | - A. Visentin
- Hematology and Clinical Immunology Unit, Department of Medicine (DIMED) University of Padua Padua Italy
| | - P. R. Scalzulli
- Department of Hematology Casa Sollievo della Sofferenza San Giovanni Rotondo Italy
| | - A. Rossi
- Hematology Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII Bergamo Italy
| | - S. Galimberti
- Division of Hematology, Department of Clinical and Experimental Medicine, University of Pisa Pisa Italy
| | | | - G. Gini
- Division of Hematology, Azienda Ospedaliera Universitaria Ospedali Riuniti Ancona Italy
| | - M. Musso
- Department of Oncology, Hematology and BMT Unit Casa di Cura La Maddalena Palermo Italy
| | - M. Sorio
- Department of Clinical and Experimental Medicine, Hematology and Bone Marrow Transplant Unit Verona Italy
| | - A. Arcari
- Hematology Unit, Ospedale Guglielmo da Saliceto Piacenza Italy
| | - V. R. Zilioli
- Division of Hematology ASST Grande Ospedale Metropolitano Niguarda Milan Italy
| | - A. Bari
- Dipartimento di Scienze Mediche e Chirurgiche Materno‐Infantili e dell'Adulto Università di Modena e Reggio Emilia Modena Italy
| | - D. Mannina
- Unit of Haematology Azienda Ospedaliera Papardo Messina Italy
| | - A. Fabbri
- Hematology Unit Azienda Ospedaliero‐Universitaria Senese Siena Italy
| | - G. Pietrantuono
- Hematology and Stem Cell Transplantation Unit IRCCS Centro di Riferimento Oncologico della Basilicata Rionero in Vulture Italy
| | - O. Annibali
- Unit of Haematology and Stem Cell Transplantation Campus Bio‐Medico University Rome Italy
| | - A. Tafuri
- University Hospital Sant'Andrea, Sapienza University of Rome Rome Italy
| | - E. Prete
- Department of Hematology and Bone Marrow Transplant Hospital Card. G. Panico Tricase Italy
| | - A. Mulè
- Division of Hematology, Azienda Villa Sofia‐Cervello Palermo Italy
| | - E. Barbolini
- Gruppo Amici dell'Ematologia GRADE Onlus Foundation Reggio Emilia Italy
| | | | - S. Luminari
- Hematology Unit Azienda Unità Sanitaria Locale ‐ IRCCS Reggio Emilia Italy
| | - F. Merli
- Hematology Unit Azienda Unità Sanitaria Locale ‐ IRCCS Reggio Emilia Italy
| |
Collapse
|
4
|
Chiappella A, Carniti C, Re A, Castellino C, Evangelista A, Ciancia R, Orsucci L, Pinto A, Usai SV, Arcari A, Ilariucci F, Rossi FG, Benedetti F, Flenghi L, Ghiggi C, Molinari AL, Stefoni V, Volpetti S, Zilioli VR, Ballerini F, Bruna R, Cavallo F, Musuraca G, Patti C, Re F, Tani M, Varettoni M, Zanni M, Dodero A, Pileri SA, Ciccone G, Corradini P. ROMIDEPSIN‐CHOEP PLUS UP‐FRONT STEM‐CELL TRANSPLANTATION IN PERIPHERAL T‐CELL LYMPHOMA (PTCL): FIRST ANALYSIS OF THE PHASE II FIL‐PTCL13 STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.130_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A. Chiappella
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Hematology and Stem Cell Transplantation Milano Italy
| | - C. Carniti
- Fondazione IRCCS, Istituto Nazionale dei Tumori di Milano Laboratory of Hematology Division of Hematology and Stem Cell Transplantation Milano Italy
| | - A. Re
- ASST Spedali Civili di Brescia Hematology Division Brescia Italy
| | - C. Castellino
- Azienda Ospedaliera S. Croce e Carle Division of Hematology Cuneo Italy
| | - A. Evangelista
- Azienda Ospedaliera e Universitaria Città della Salute e della Scienza and CPO Piemonte Unit of Clinical Epidemiology Torino Italy
| | - R. Ciancia
- Centro di Riferimento Oncologico (CRO) IRCCS Onco‐hematology and Stem Cell Transplantation and Cellular Therapies Aviano Italy
| | - L. Orsucci
- Azienda Ospedaliera e Universitaria Città della Salute e della Scienza Division of Hematology Torino Italy
| | - A. Pinto
- Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS Hematology‐Oncology & Stem Cell Transplantation Unit Napoli Italy
| | - S. V. Usai
- Ospedale Oncologico Armando Businco Hematology Cagliari Italy
| | - A. Arcari
- Ospedale Guglielmo da Saliceto Hematology Unit Piacenza Italy
| | - F. Ilariucci
- Azienda USL‐IRCCS, Hematology Reggio Emilia Italy
| | - F. G. Rossi
- Fondazione IRCCS Cà Granda OM Policlinico Division of Hematology Milano Italy
| | - F. Benedetti
- Azienda Ospedaliera Universitaria di Verona Hematology and Stem Cell Transplantation Verona Italy
| | - L. Flenghi
- Azienda Ospedaliera di Perugia Hematology Perugia Italy
| | - C. Ghiggi
- IRCCS Ospedale Policlinico San Martino Hematology Genova Italy
| | | | - V. Stefoni
- University of Bologna Institute of Hematology "Seràgnoli" Bologna Italy
| | - S. Volpetti
- Presidio Ospedaliero Universitario "Santa Maria della Misericordia” di Udine ASUFC Clinic of Hematology Udine Italy
| | - V. R. Zilioli
- ASST Grande Ospedale Metropolitano Niguarda Division of Hematology Milano Italy
| | - F. Ballerini
- IRCCS Ospedale Policlinico San Martino Clinic of Hematology Genova Italy
| | - R. Bruna
- Ospedale Maggiore Della Carità Division of Hematology Novara Italy
| | - F. Cavallo
- University of Torino Azienda Ospedaliera e Universitaria Città della Salute e della Scienza Division of Hematology Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - G. Musuraca
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" Division of Hematology Meldola Italy
| | - C. Patti
- Azienda Villa Sofia Cervello Division of Onco‐Hematology Palermo Italy
| | - F. Re
- Azienda Ospedaliera‐Universitaria di Parma Hematology and CTMO Parma Italy
| | - M. Tani
- Ospedale Santa Maria delle Croci Hematology Unit Ravenna Italy
| | - M. Varettoni
- Fondazione IRCCS Policlinico San Matteo Division of Hematology Pavia Italy
| | - M. Zanni
- Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo Division of Hematology Alessandria Italy
| | - A. Dodero
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Hematology and Stem Cell Transplantation Milano Italy
| | - S. A. Pileri
- European Institute of Oncology IRCCS Division of Haematopathology Milano Italy
| | - G. Ciccone
- Azienda Ospedaliera e Universitaria Città della Salute e della Scienza and CPO Piemonte Unit of Clinical Epidemiology Torino Italy
| | - P. Corradini
- Chair of Hematology University of Milano Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Division of Hematology and Stem Cell Transplantation Milano Italy
| |
Collapse
|
5
|
Tucci A, Merli F, Fabbri A, Mancuso S, Sartori R, Storti S, Luminari S, Mammi C, Marcheselli L, Arcari A, Cavallo F, Zilioli VR, Bottelli C, Re A, Gini G, Cox MC, Puccini B, Pagani C, Balzarotti M, Spina M, Rossi G. DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN LATE‐OCTOGENARIAN (LO) PATIENTS: A SUBSTUDY OF THE “ELDERLY PROJECT” BY THE FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2021. [DOI: 10.1002/hon.95_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. Tucci
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| | - F. Merli
- Azienda Unità Sanitaria Locale – IRCCS Hematology Unit Reggio Emilia Italy
| | - A. Fabbri
- zienda Ospedaliera Universitaria Senese and University of Siena Unit of Hematology Siena Italy
| | - S. Mancuso
- Department Pro.Mi.Se Univeristy of Palermo Haematology Division Palermo Italy
| | - R. Sartori
- Veneto Institute of Oncology IOV‐IRCCS Department of Clinical and Experimental Oncology Oncohematology Unit Castelfranco Veneto (TV) Italy
| | - S. Storti
- Università Cattolica Onco‐hematology Unit Campobasso‐Roma Italy
| | - S. Luminari
- University of Modena and Reggio Emilia Azienda Unità Sanitaria Locale – IRCCS Department CHIMOMO Hematology Unit Reggio Emilia Italy
| | - C. Mammi
- Gruppo Amici dell'Ematologia GRADE‐ Onlus Foundation Hematology Unit Reggio Emilia Italy
| | - L. Marcheselli
- Fondazione Italiana Linfomi Onlus Fondazione Italiana Linfomi Onlus Modena Italy
| | - A. Arcari
- Ospedale Guglielmo da Saliceto Hematology Unit Piacenza Italy
| | - F. Cavallo
- University of Torino/AOU “Città della Salute e della Scienza di Torino” Division of Hematology Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - V. R. Zilioli
- ASST Grande Ospedale Metropolitano Niguarda Division of Hematology Milano Italy
| | - C. Bottelli
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| | - A. Re
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| | - G. Gini
- Azienda Ospedaliera Universitaria Ospedali Riuniti Division of Hematology Ancona Italy
| | - M. C. Cox
- Azienda Ospedaliera Universitaria S.Andrea Hematology Unit Roma Italy
| | - B. Puccini
- Careggi University Hospital Hematology Unit Firenze Italy
| | - C. Pagani
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| | - M. Balzarotti
- Humanitas Clinical Research Hospital‐IRCCS Department of Medical Oncology and Hematology Rozzano (MI) Italy
| | - M. Spina
- Centro di Riferimento Oncologico di Aviano (CRO) IRCCS Division of Medical Oncology and Immune‐related Tumors Aviano (PN) Italy
| | - G. Rossi
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| |
Collapse
|
6
|
Zilioli VR, Albano D, Arcari A, Merli F, Coppola A, Besutti G, Marcheselli L, Gramegna D, Muzi C, Manicone M, Camalori M, Ciammella P, Colloca G, Tucci A. SARCOPENIA IS AN INDEPENDENT PROGNOSTIC FACTOR IN ELDERLY MALE PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: RESULTS FROM A MULTICENTER EXPERIENCE. Hematol Oncol 2021. [DOI: 10.1002/hon.116_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- V. R. Zilioli
- ASST Grande Ospedale Metropolitano Niguarda, Hematology Milan Italy
| | - D. Albano
- ASST Spedali Civili, Nuclear Medicine Brescia Italy
| | - A. Arcari
- Ospedale Guglielmo da Saliceto, Hematology Piacenza Italy
| | - F. Merli
- Azienda USL ‐ IRCCS di Reggio Emilia, Hematology, Reggio Emilia Italy
| | - A. Coppola
- ASST Grande Ospedale Metropolitano Niguarda, Radiology Milan Italy
| | - G. Besutti
- University of Modena and Reggio Emilia, Clinical and Experimental PhD program Modena Italy
| | - L. Marcheselli
- Fondazione Italiana Linfomi Onlus, Trial Office Modena Modena Italy
| | - D. Gramegna
- ASST Spedali Civili, Hematology Brescia Italy
| | - C. Muzi
- ASST Grande Ospedale Metropolitano Niguarda, Hematology Milan Italy
| | - M. Manicone
- University of Modena and Reggio Emilia, Clinical and Experimental PhD program Modena Italy
| | - M. Camalori
- ASST Grande Ospedale Metropolitano Niguarda, Radiology Milan Italy
| | - P. Ciammella
- Azienda USL ‐ IRCCS di Reggio Emilia, Radiotherapy, Reggio Emilia Italy
| | - G. Colloca
- Fondazione Policlinico Universitario A. Gemelli, IRCCS, Geriatrics Rome Italy
| | - A. Tucci
- ASST Spedali Civili, Hematology Brescia Italy
| |
Collapse
|
7
|
Merli F, Tucci A, Arcari A, Rigacci L, Cavallo F, Cabras G, Alvarez I, Fabbri A, Re A, Ferrero S, Puccini B, Usai SV, Ferrari A, Cencini E, Pennese E, Zilioli VR, Marino D, Balzarotti M, Cox MC, Zanni M, Rocco A, Lleshi A, Botto B, Hohaus S, Merli M, Sartori R, Gini G, Nassi L, Musuraca G, Tani M, Bottelli C, Kovalchuk S, Re F, Flenghi L, Molinari A, Tarantini G, Chimienti E, Marcheselli L, Mammi C, Luminari S, Spina M. THE ELDERLY PROGNOSTIC INDEX (EPI) PREDICTS EARLY MORTALITY IN OLDER PATIENTS WITH DLBCL. A SUBSTUDY OF THE ELDERLY PROJECT BY THE FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2021. [DOI: 10.1002/hon.85_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
8
|
Martelli M, Zucca E, Botto B, Kryachok I, Ceriani L, Balzarotti M, Tucci A, Cabras MG, Zilioli VR, Rusconi C, Angrilli F, Arcaini L, Iwanicka AD, Ferreri A, Merli F, Zhao W, Hodgson D, Ionescu C, Fosså A, Cwynarski K, Mikhaeel G, Jerkeman M, Janikova A, Hüttmann A, Ciccone G, Metser U, Barrington S, Malkowski B, Versari A, Esposito F, Cozens K, Ielmini N, Ricardi R, Cavalli F, Johnson P, Davies A. IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.49_2879] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|